rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NPCE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      NeuroPace CFO Patrick Williams buys $99,148 in company stock
      18h agoInvesting.comNPCE
      Mizuho cuts NeuroPace stock price target to $12 on weak quarter
      Nov 16Investing.comNPCE
      Why is NeuroPace stock plummeting 40% today?
      Nov 13Investing.comNPCE
      KeyBanc cuts NeuroPace stock price target on lowered estimates
      Nov 13Investing.comNPCE
      NeuroPace Shares Plunge 33.61% After-Hours: Here's What Investors Should Know
      Nov 13BenzingaNPCE
      What NeuroPace (NPCE) Said on Its Q3 Earnings Call
      Nov 13Yahoo FinanceNPCE
      Neuropace earnings beat, revenue fell short of estimates
      Nov 13Investing.comNPCE
      NeuroPace Q3 2026 slides: growth vision clashes with revenue miss
      Nov 13Investing.comNPCE
      NeuroPace, Inc. (NPCE) Reports Q3 Loss, Misses Revenue Estimates

      NeuroPace (NPCE) delivered earnings and revenue surprises of +50.00% and -14.59%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 12Yahoo FinanceNPCE
      NeuroPace Inc.: Q3 Earnings Snapshot
      Nov 12Yahoo FinanceNPCE
      NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026
      Oct 29Yahoo FinanceNPCE
      KeyBanc initiates NeuroPace stock coverage with overweight rating
      Sep 18Investing.comNPCE
      KeyBanc Initiates NeuroPace at Overweight With $18 Price Target
      Sep 18Yahoo FinanceNPCE
      Cantor Fitzgerald reiterates Overweight on NeuroPace stock at $21
      Sep 15Investing.comNPCE
      Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?

      NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Sep 10Yahoo FinanceNPCE
      NeuroPace at Cantor healthcare conference: growth, data and FDA path
      Sep 9Investing.comNPCE
      NeuroPace at Wells Fargo conference: IGE push faces FDA test
      Sep 8Investing.comNPCEWFC
      Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

      NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.

      Sep 4Yahoo FinanceNPCE

      This is the newest page. Registered accounts read further back.